Evidence map›Paper›PMID 33803158›Full record

ArticleNanomaterials (Basel, Switzerland)2021

CdSe Quantum Dots in Human Models Derived from ALS Patients: Characterization, Nuclear Penetration Studies and Multiplexing.

Carlota Tosat-Bitrián, Alicia Avis-Bodas, Gracia Porras, Daniel Borrego-Hernández, Alberto García-Redondo, Angeles Martín-Requero, Valle Palomo

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carlota Tosat-BitriánCentro de Investigaciones Biológicas Margarita Salas CSIC, C/Ramiro de Maeztu 9, 28040 Madrid, Spain.ORCID 0000-0002-0525-3512
Alicia Avis-BodasCentro de Investigaciones Biológicas Margarita Salas CSIC, C/Ramiro de Maeztu 9, 28040 Madrid, Spain.ORCID 0000-0002-9275-5413
Gracia PorrasCentro de Investigaciones Biológicas Margarita Salas CSIC, C/Ramiro de Maeztu 9, 28040 Madrid, Spain.
Daniel Borrego-HernándezNeurology Department, ALS Unit, CIBERER U-723, Health Research Institute, 28041 Madrid, Spain.
Alberto García-RedondoNeurology Department, ALS Unit, CIBERER U-723, Health Research Institute, 28041 Madrid, Spain.
Angeles Martín-RequeroCentro de Investigaciones Biológicas Margarita Salas CSIC, C/Ramiro de Maeztu 9, 28040 Madrid, Spain.ORCID 0000-0002-3416-9440
Valle PalomoCentro de Investigaciones Biológicas Margarita Salas CSIC, C/Ramiro de Maeztu 9, 28040 Madrid, Spain.ORCID 0000-0002-1473-4086

Funding

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CB18/05/00040Comunidad de Madrid B2017/BMD-3813Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona LCF/BQ/PR18/11640007Ministerio de Educación, Cultura y Deporte FPU18/06310
6 · The paper itself

Abstract

CdSe quantum dots (QDs) are valuable tools for deciphering molecular mechanisms in cells. Their conjugation with antibodies offers a unique staining source with optimal characteristics, including increased photostability and narrow emission spectra, allowing for improved multiplexing capabilities using a single excitation source. In combination with pathology models derived from patients, they have great potential to contribute to quantitative molecular profiling and promote personalized medicine. However, the commercial availability of diverse CdSe QDs is still limited and characterization techniques must be performed to these materials or the conjugates developed in the lab to assure a proper function and reproducibility. Furthermore, while there is significant data of QDs experiments in cell lines, the literature with primary human cells is scarce, and QD behavior in these systems may be different. Rigorous characterization data of commercially available QDs and their conjugates with biomolecules of interest is needed in order to establish their potential for target labelling and expand their use among research labs. Here we compare the characterization and labelling performance of different QD conjugates in SH-SY5Y cell line, fibroblasts and immortalized lymphocytes derived from amyotrophic lateral sclerosis patients.

Indexed as

ALScharacterizationhuman primary cellsmultiplexingquantum dots

Identifiers

PMID33803158
PMCPMC7998605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.